David S Baldwin

Summary

Affiliation: University of Southampton
Country: UK

Publications

  1. ncbi request reprint Paroxetine in social phobia/social anxiety disorder. Randomised, double-blind, placebo-controlled study. Paroxetine Study Group
    D Baldwin
    Mental Health Group, University of Southampton, Royal South Hants Hospital
    Br J Psychiatry 175:120-6. 1999
  2. ncbi request reprint Discontinuation symptoms in depression and anxiety disorders
    David S Baldwin
    Clinical Neurosciences Division, School of Medicine, University of Southampton, UK
    Int J Neuropsychopharmacol 10:73-84. 2007
  3. doi request reprint Inhalation of 7.5% carbon dioxide increases alerting and orienting attention network function
    Matthew Garner
    Clinical and Experimental Sciences, Faculty of Medicine, University of Southampton, Southampton, SO17 1BJ, UK
    Psychopharmacology (Berl) 223:67-73. 2012
  4. ncbi request reprint A double-blind, randomized, parallel-group, flexible-dose study to evaluate the tolerability, efficacy and effects of treatment discontinuation with escitalopram and paroxetine in patients with major depressive disorder
    David S Baldwin
    Clinical Neuroscience Division, University of Southampton, Royal South Hants Hospital, Southampton, UK
    Int Clin Psychopharmacol 21:159-69. 2006
  5. doi request reprint A cross-sectional study of mental health and well-being and their associations in the UK veterinary profession
    David J Bartram
    Division of Clinical Neurosciences, School of Medicine, RSH Hospital, University of Southampton, Brintons Terrace, Southampton SO14 0YG, UK
    Soc Psychiatry Psychiatr Epidemiol 44:1075-85. 2009
  6. doi request reprint Validation of the Warwick-Edinburgh Mental Well-being Scale (WEMWBS) as an overall indicator of population mental health and well-being in the UK veterinary profession
    David J Bartram
    University Department of Mental Health, Division of Clinical Neurosciences, School of Medicine, University of Southampton, Royal South Hants Hospital, Brintons Terrace, Southampton SO14 0YG, UK
    Vet J 187:397-8. 2011
  7. doi request reprint How long should a trial of escitalopram treatment be in patients with major depressive disorder, generalised anxiety disorder or social anxiety disorder? An exploration of the randomised controlled trial database
    David S Baldwin
    Clinical Neuroscience Division, School of Medicine, University of Southampton, Southampton, UK
    Hum Psychopharmacol 24:269-75. 2009
  8. ncbi request reprint Evidence-based pharmacological treatment of anxiety disorders, post-traumatic stress disorder and obsessive-compulsive disorder: A revision of the 2005 guidelines from the British Association for Psychopharmacology
    David S Baldwin
    1Faculty of Medicine, University of Southampton, Southampton, UK
    J Psychopharmacol 28:403-39. 2014
  9. doi request reprint Does early improvement predict endpoint response in patients with generalized anxiety disorder (GAD) treated with pregabalin or venlafaxine XR?
    David S Baldwin
    University of Southampton, UK
    Eur Neuropsychopharmacol 22:137-42. 2012
  10. ncbi request reprint Escitalopram and paroxetine in the treatment of generalised anxiety disorder: randomised, placebo-controlled, double-blind study
    David S Baldwin
    Neuroscience Division, School of Medicine, University of Southampton, Royal South Hants Hospital, Graham Road, Southampton SO14 0YG, UK
    Br J Psychiatry 189:264-72. 2006

Collaborators

Detail Information

Publications54

  1. ncbi request reprint Paroxetine in social phobia/social anxiety disorder. Randomised, double-blind, placebo-controlled study. Paroxetine Study Group
    D Baldwin
    Mental Health Group, University of Southampton, Royal South Hants Hospital
    Br J Psychiatry 175:120-6. 1999
    ..Preliminary studies have suggested that paroxetine may be effective in social phobia/social anxiety disorder...
  2. ncbi request reprint Discontinuation symptoms in depression and anxiety disorders
    David S Baldwin
    Clinical Neurosciences Division, School of Medicine, University of Southampton, UK
    Int J Neuropsychopharmacol 10:73-84. 2007
    ..Thus, discontinuation profiles differ between antidepressants of the same class and are broadly similar in different disorders. No evidence was seen for a higher discontinuation burden with longer treatment...
  3. doi request reprint Inhalation of 7.5% carbon dioxide increases alerting and orienting attention network function
    Matthew Garner
    Clinical and Experimental Sciences, Faculty of Medicine, University of Southampton, Southampton, SO17 1BJ, UK
    Psychopharmacology (Berl) 223:67-73. 2012
    ..However the effects on broader cognitive (non-emotional) processes that characterize anxiety are not known...
  4. ncbi request reprint A double-blind, randomized, parallel-group, flexible-dose study to evaluate the tolerability, efficacy and effects of treatment discontinuation with escitalopram and paroxetine in patients with major depressive disorder
    David S Baldwin
    Clinical Neuroscience Division, University of Southampton, Royal South Hants Hospital, Southampton, UK
    Int Clin Psychopharmacol 21:159-69. 2006
    ..During taper and cessation of treatment, patients in the paroxetine group demonstrated significantly more discontinuation symptoms relative to escitalopram based on the Discontinuation Emergent Signs and Symptoms scores...
  5. doi request reprint A cross-sectional study of mental health and well-being and their associations in the UK veterinary profession
    David J Bartram
    Division of Clinical Neurosciences, School of Medicine, RSH Hospital, University of Southampton, Brintons Terrace, Southampton SO14 0YG, UK
    Soc Psychiatry Psychiatr Epidemiol 44:1075-85. 2009
    ..We aimed to assess the contribution of mental health and well-being to the elevated risk, through a postal questionnaire survey of a large stratified random sample of veterinary surgeons practising within the UK...
  6. doi request reprint Validation of the Warwick-Edinburgh Mental Well-being Scale (WEMWBS) as an overall indicator of population mental health and well-being in the UK veterinary profession
    David J Bartram
    University Department of Mental Health, Division of Clinical Neurosciences, School of Medicine, University of Southampton, Royal South Hants Hospital, Brintons Terrace, Southampton SO14 0YG, UK
    Vet J 187:397-8. 2011
    ..The results support the validity of the scale as an overall indicator of population mental health and well-being for this occupational group...
  7. doi request reprint How long should a trial of escitalopram treatment be in patients with major depressive disorder, generalised anxiety disorder or social anxiety disorder? An exploration of the randomised controlled trial database
    David S Baldwin
    Clinical Neuroscience Division, School of Medicine, University of Southampton, Southampton, UK
    Hum Psychopharmacol 24:269-75. 2009
    ....
  8. ncbi request reprint Evidence-based pharmacological treatment of anxiety disorders, post-traumatic stress disorder and obsessive-compulsive disorder: A revision of the 2005 guidelines from the British Association for Psychopharmacology
    David S Baldwin
    1Faculty of Medicine, University of Southampton, Southampton, UK
    J Psychopharmacol 28:403-39. 2014
    ..They may also serve as a source of information for patients, their carers, and medicines management and formulary committees. ..
  9. doi request reprint Does early improvement predict endpoint response in patients with generalized anxiety disorder (GAD) treated with pregabalin or venlafaxine XR?
    David S Baldwin
    University of Southampton, UK
    Eur Neuropsychopharmacol 22:137-42. 2012
    ....
  10. ncbi request reprint Escitalopram and paroxetine in the treatment of generalised anxiety disorder: randomised, placebo-controlled, double-blind study
    David S Baldwin
    Neuroscience Division, School of Medicine, University of Southampton, Royal South Hants Hospital, Graham Road, Southampton SO14 0YG, UK
    Br J Psychiatry 189:264-72. 2006
    ..It is uncertain whether higher doses of selective serotonin reuptake inhibitors have greater efficacy in generalised anxiety disorder...
  11. ncbi request reprint Pharmacological treatment of generalized anxiety disorder
    David S Baldwin
    Clinical Neuroscience Division, School of Medicine, University of Southampton, Southampton, UK
    Curr Top Behav Neurosci 2:453-67. 2010
    ....
  12. doi request reprint Research in anxiety disorders: from the bench to the bedside
    Matthew Garner
    School of Psychology and Division of Clinical Neurosciences, School of Medicine, University of Southampton, UK
    Eur Neuropsychopharmacol 19:381-90. 2009
    ..Clinical and neurobiological predictors of active treatment and placebo response are considered...
  13. doi request reprint Further validation of the Warwick-Edinburgh Mental Well-being Scale (WEMWBS) in the UK veterinary profession: Rasch analysis
    David J Bartram
    Faculty of Medicine, University Department of Psychiatry, University of Southampton, Academic Centre, College Keep, 4 12 Terminus Terrace, Southampton, SO14 3DT, UK
    Qual Life Res 22:379-91. 2013
    ....
  14. pmc Inhalation of 7.5% carbon dioxide increases threat processing in humans
    Matthew Garner
    Clinical Neuroscience Division, School of Medicine, University of Southampton, Southampton, UK
    Neuropsychopharmacology 36:1557-62. 2011
    ..Findings extend evidence that CO(2) triggers fear behavior in animals via direct innervation of a distributed fear network that mobilizes the detection of and allocation of processing resources toward environmental threat in humans...
  15. ncbi request reprint Evidence-based guidelines for the pharmacological treatment of anxiety disorders: recommendations from the British Association for Psychopharmacology
    David S Baldwin
    Division of Clinical Neurosciences, University of Southampton, Southampton, UK
    J Psychopharmacol 19:567-96. 2005
    ..The guidelines cover the diagnosis of anxiety disorders and key steps in clinical management, including acute treatment, relapse prevention and approaches for patients who do not respond to first-line treatments...
  16. doi request reprint Attentional biases in clinical populations with alcohol use disorders: is co-morbidity ignored?
    Julia M A Sinclair
    Mental Health Group, Division of Clinical Neurosciences, School of Medicine, University of Southampton, UK
    Hum Psychopharmacol 25:515-24. 2010
    ..To identify how psychiatric co-morbidity was identified and assessed, in studies of attentional bias in clinical samples of patients with alcohol use disorders (AUDs)...
  17. ncbi request reprint The pharmacologic treatment of patients with generalized anxiety disorder: where are we now and where are we going?
    David S Baldwin
    Department of Psychiatry, Royal South Hants Hospital, Southampton, UK
    CNS Spectr 14:5-12. 2009
    ..Future guidelines will be influenced by emerging data with both established and novel drug treatments, and through better identification of patient groups that are likely to respond preferentially to particular interventions...
  18. ncbi request reprint Symptoms of fatigue and sleepiness in major depressive disorder
    David S Baldwin
    Faculty of Medicine, Health, and Life Sciences, University of Southampton, UK
    J Clin Psychiatry 67:9-15. 2006
    ....
  19. doi request reprint Defensive startle response to emotional social cues in social anxiety
    Matthew Garner
    School of Psychology, University of Southampton, UK Division of Clinical Neuroscience, School of Medicine, University of Southampton, UK
    Psychiatry Res 186:150-2. 2011
    ..Socially anxious individuals exhibited larger startle responses to emotional (positive and negative) relative to neutral social cues, compared to non-anxious individuals...
  20. doi request reprint Manifesto for a European anxiety disorders research network
    David S Baldwin
    Clinical Neuroscience Division, University of Southampton School of Medicine, Southampton, UK
    Eur Neuropsychopharmacol 20:426-32. 2010
    ..The Anxiety Disorders Research Network (ADRN) has been adopted within the ECNP-NI: this consensus statement summarises its overall aims and objectives...
  21. ncbi request reprint Sexual dysfunction associated with antidepressant drugs
    David S Baldwin
    University Department of Mental Health, RSH Hospital, RSH Hospital, Graham Road, Southampton, SO14 0YG, UK
    Expert Opin Drug Saf 3:457-70. 2004
    ....
  22. ncbi request reprint Escitalopram therapy for major depression and anxiety disorders
    David S Baldwin
    Clinical Neuroscience Division, University Department of Mental Health, Royal South Hants Hospital, Southampton, England
    Ann Pharmacother 41:1583-92. 2007
    ..Randomized controlled clinical trials have demonstrated that escitalopram is efficacious in a range of mood and anxiety disorders, but the individual trials are insufficiently large to allow a full exploration of its tolerability...
  23. ncbi request reprint Escitalopram in the treatment of generalized anxiety disorder
    David S Baldwin
    Division of Clinical Neurosciences, University Department of Mental Health, RSH Hospital, Graham Road, Southampton, SO14 0YG, UK
    Expert Rev Neurother 5:443-9. 2005
    ..In summary, escitalopram is effective and well tolerated in both the short- and long-term treatment of generalized anxiety disorder, and has advantages over benzodiazepines and the selective serotonin reuptake inhibitor paroxetine...
  24. ncbi request reprint Quantifying subjective assessment of sleep and life-quality in antidepressant-treated depressed patients
    Andrew G Mayers
    University Department of Psychiatry, University of Southampton, UK
    Hum Psychopharmacol 18:21-7. 2003
    ..These results confirm the extent of subjectively reported sleep disruption in depression and demonstrate the merit of combining the amended PghSD and QOLI to quantify sleep perceptions...
  25. ncbi request reprint Can we distinguish anxiety from depression?
    David S Baldwin
    Department of Psychiatry, University of Southampton, Hampshire, United Kingdom
    Psychopharmacol Bull 36:158-65. 2002
    ..There is still uncertainty regarding the neurobiological cause, but it is probably linked to dysregulation in the serotonergic and noradrenergic systems...
  26. doi request reprint Lu AA21004, a multimodal psychotropic agent, in the prevention of relapse in adult patients with generalized anxiety disorder
    David S Baldwin
    Clinical and Experimental Sciences, Faculty of Medicine, University of Southampton, Southampton, UK
    Int Clin Psychopharmacol 27:197-207. 2012
    ..In this study, Lu AA21004 5 or 10 mg/day was efficacious in preventing relapse and was well tolerated in the maintenance treatment of GAD...
  27. doi request reprint Evidence-based pharmacological treatment of generalized anxiety disorder
    David S Baldwin
    Clinical Neuroscience Division, School of Medicine, University of Southampton, UK
    Int J Neuropsychopharmacol 14:697-710. 2011
    ..There have been few investigations of the further management of patients who have not responded to first-line treatment, but switching to another evidence-based treatment, or augmentation approaches may be beneficial...
  28. ncbi request reprint Antidepressants and their effect on sleep
    Andrew G Mayers
    Perinatal Mental Health, University of Southampton, UK
    Hum Psychopharmacol 20:533-59. 2005
    ....
  29. doi request reprint Impaired identification of fearful faces in Generalised Social Phobia
    Matthew Garner
    Division of Clinical Neuroscience, School of Medicine, University of Southampton, SO17 1BJ, United
    J Affect Disord 115:460-5. 2009
    ..The present study is novel in using a signal detection approach to clarify whether Generalised Social Phobia (GSP) is associated with biased identification of emotionally ambiguous facial expressions...
  30. ncbi request reprint Benzodiazepines: risks and benefits. A reconsideration
    David S Baldwin
    1Faculty of Medicine, University of Southampton, Southampton, UK
    J Psychopharmacol 27:967-71. 2013
    ....
  31. doi request reprint A neuroimmunological perspective on anxiety disorders
    Ruihua Hou
    University Department of Psychiatry, Faculty of Medicine, University of Southampton, Southampton, UK
    Hum Psychopharmacol 27:6-14. 2012
    ....
  32. ncbi request reprint Effect of short-term SSRI treatment on cognitive bias in generalised anxiety disorder
    Karin Mogg
    Centre for the Study of Emotion and Motivation, School of Psychology, University of Southampton, Highfield, Southampton, SO171BJ, UK
    Psychopharmacology (Berl) 176:466-70. 2004
    ..Cognitive theories of anxiety, which provide the basis of cognitive-behaviour therapy, propose that such processing biases play an important role in causing and maintaining anxiety...
  33. ncbi request reprint Escitalopram: efficacy and tolerability in the treatment of depression
    David S Baldwin
    Community Clinical Sciences, Research Division, Faculty of Medicine, Health and Biological Sciences, University Department of Mental Health, University of Southampton, Royal South Hants Hospital, Southampton SO14 0YG
    Hosp Med 63:668-71. 2002
    ..This review describes the properties of escitalopram, summarizes the results of randomized controlled trials, and suggests that escitalopram has advantages over citalopram in the treatment of depression...
  34. ncbi request reprint Agomelatine in the treatment of mood and anxiety disorders
    David S Baldwin
    Clinical Neuroscience Division, School of Medicine, University of Southampton, Southhampton
    Br J Hosp Med (Lond) 71:153-6. 2010
    ..What is its potential role in clinical practice?..
  35. doi request reprint Quality of case reports of adverse drug reactions with psychotropic drugs: a 25-year review
    Bilal Talat
    Avon and Wiltshire Mental Health Partnership NHS Trust, Bristol, UK Faculty of Medicine, University of Southampton, Southampton, UK
    Hum Psychopharmacol 28:413-20. 2013
    ..Reports that are cited frequently become influential because of their potential clinical relevance, rather than due to their methodological quality...
  36. doi request reprint The effect of focused attention and open monitoring meditation on attention network function in healthy volunteers
    Ben Ainsworth
    Psychology, Faculty of Social and Human Sciences, University of Southampton, Southampton SO17 1BJ, UK Clinical and Experimental Sciences, Faculty of Medicine, University of Southampton, UK Electronic address
    Psychiatry Res 210:1226-31. 2013
    ..Our results suggest that mindfulness meditation might usefully target deficits in executive attention that characterise mood and anxiety disorders. ..
  37. doi request reprint Psychosocial working conditions and work-related stressors among UK veterinary surgeons
    David J Bartram
    Division of Clinical Neurosciences, School of Medicine, University of Southampton, RSH Hospital, Brintons Terrace, Southampton SO14 0YG, UK
    Occup Med (Lond) 59:334-41. 2009
    ..Anecdotally, veterinary surgeons report high levels of work-related stress...
  38. ncbi request reprint Assessing subjective sleep reports in the first-degree relatives of antidepressant-treated depressed outpatients
    Andrew G Mayers
    University Department of Psychiatry, University of Southampton, UK
    Hum Psychopharmacol 18:207-14. 2003
    ..Reports of poor sleep may be associated with reports of poor mood in depression, but in non-depressed individuals the association may be with a feeling of weariness...
  39. ncbi request reprint Evidence-based pharmacotherapy of Generalized Anxiety Disorder
    David S Baldwin
    Clinical Neurosciences Division, Faculty of Medicine, Health and Life Sciences, University of Southampton, UK
    Int J Neuropsychopharmacol 8:293-302. 2005
    ..The management of patients who do not respond to first-line treatment is uncertain, but some patients may benefit from certain tricyclic antidepressants, buspirone, or pregabalin...
  40. ncbi request reprint Recurrent brief depression--more investigations in clinical samples are now required
    David S Baldwin
    Psychol Med 33:383-6. 2003
  41. ncbi request reprint Evidence-based guidelines for anxiety disorders: can they improve clinical outcomes?
    David S Baldwin
    Department of Psychiatry, Royal South Hants Hospital, Southampton, United Kingdom
    CNS Spectr 11:34-9. 2006
    ....
  42. ncbi request reprint What is the threshold for symptomatic response and remission for major depressive disorder, panic disorder, social anxiety disorder, and generalized anxiety disorder?
    Borwin Bandelow
    Department of Psychiatry and Psychotherapy, University of Gottingen, Gottingen, Germany
    J Clin Psychiatry 67:1428-34. 2006
    ..We also sought to compare the standardized effect sizes of escitalopram for these 4 psychiatric disorders...
  43. ncbi request reprint Which factors predict placebo response in anxiety disorders and major depression? An analysis of placebo-controlled studies of escitalopram
    Dan J Stein
    Department of Psychiatry, University of Cape Town, South Africa
    J Clin Psychiatry 67:1741-6. 2006
    ....
  44. ncbi request reprint Estimating the prevalence and impact of antidepressant-induced sexual dysfunction in 2 European countries: a cross-sectional patient survey
    Valerie S L Williams
    RTI Health Solutions, Research Triangle Park, NC 27709 2194, USA
    J Clin Psychiatry 67:204-10. 2006
    ..The aim of this study was to estimate the prevalence and impact of sexual dysfunction during antidepressant treatment in 2 European countries...
  45. ncbi request reprint The overlap of obsessive-compulsive disorder and social phobia and its treatment
    David S Baldwin
    Strategic Center of Excellence of Psychiatry, Department of Psychiatry, Mount Sinai School of Medicine, New York, NY, USA
    CNS Spectr 13:47-53. 2008
    ..Psychologic intervention should draw on the range of cognitive and behavioral approaches required for optimal outcomes in OCD and social phobia, as discrete conditions...
  46. ncbi request reprint Effects of venlafaxine extended release on resilience in posttraumatic stress disorder: an item analysis of the Connor-Davidson Resilience Scale
    Jonathan Davidson
    Department of Psychiatry and Behavioral Sciences, Duke University Medical Center, Trent Drive, 4th Floor, Room 4082B, Durham, NC 27710, USA
    Int Clin Psychopharmacol 23:299-303. 2008
    ..The findings suggest that assessment of treatment response might be enhanced by routine evaluation of resilience...
  47. ncbi request reprint Cost-effectiveness analysis of escitalopram compared with paroxetine in treatment of generalized anxiety disorder in the United Kingdom
    Tine Rikke Jørgensen
    International Department of Health Economics and Epidemiology, H Lundbeck A S, Copenhagen, Denmark
    Ann Pharmacother 40:1752-8. 2006
    ..Generalized anxiety disorder (GAD) is associated with substantial economic burden...
  48. ncbi request reprint Suicide in depressive disorders: a retrospective case-control study of 127 suicides
    Julia M A Sinclair
    Centre for Suicide Research, UK
    J Affect Disord 87:107-13. 2005
    ..Depressive disorders are associated with a significant risk of suicide. Inpatient status and recent discharge from hospital have been identified as times of high risk of suicide within the course of illness...
  49. ncbi request reprint Which antidepressants have demonstrated superior efficacy? A review of the evidence
    Stuart A Montgomery
    Imperial College School of Medicine, University of London, UK
    Int Clin Psychopharmacol 22:323-9. 2007
    ..This review of published data found evidence that only a very few antidepressants are shown to be more effective than others...
  50. doi request reprint Antidepressant medications and other treatments of depressive disorders: a CINP Task Force report based on a review of evidence
    Norman Sartorius
    Chairperson of CINP Task Force, 14 Chemin Colladon, Geneva, Switzerland
    Int J Neuropsychopharmacol 10:S1-207. 2007
  51. ncbi request reprint Consensus statement and research needs: the role of dopamine and norepinephrine in depression and antidepressant treatment
    David J Nutt
    Psychopharmacology Unit, School of Medical Sciences, University of Bristol, Bristol, UK
    J Clin Psychiatry 67:46-9. 2006
    ..In addition, the faculty discussed the importance of patient psychoeducation and self-management as well as the ways in which disease models of depression affect treatment...
  52. doi request reprint Do SSRIs or antidepressants in general increase suicidality? WPA Section on Pharmacopsychiatry: consensus statement
    Hans Jurgen Moller
    Department of Psychiatry, Ludwig Maximilians University Munchen, Nussbaumstrasse 7, 80336 Munich, Germany
    Eur Arch Psychiatry Clin Neurosci 258:3-23. 2008
    ..It is the major problem facing efforts to identify the possible 'suicidal effects' of antidepressants...
  53. doi request reprint Efficacy of pregabalin in depressive symptoms associated with generalized anxiety disorder: a pooled analysis of 6 studies
    Dan J Stein
    Department of Psychiatry and Mental Health, University of Cape Town, Cape Town, South Africa
    Eur Neuropsychopharmacol 18:422-30. 2008
    ..In conclusion, pregabalin, an alternative treatment option for GAD with a novel mechanism of action, also demonstrated efficacy in treating depressive symptoms typically encountered in GAD patients...
  54. ncbi request reprint Suicide in schizophrenia: a retrospective case-control study of 51 suicides
    Julia M A Sinclair
    Department of Psychiatry, Warneford Hospital, Oxford OX3 7JX, UK
    Schizophr Bull 30:803-11. 2004
    ..Suicide of individuals is difficult to predict in patients with schizophrenia. Young men appear particularly vulnerable at times of inpatient care. Depressive symptoms and previous suicide attempts are significant risk factors...